Stocks and Investing
Stocks and Investing
Wed, May 8, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Scott Schoenhaus Maintained (ABCL) at Buy with Decreased Target to $7 on, May 8th, 2024
Scott Schoenhaus of Keybanc, Maintained "AbCellera Biologics Inc." (ABCL) at Buy with Decreased Target from $8 to $7 on, May 8th, 2024.
Scott has made no other calls on ABCL in the last 4 months.
There are 2 other peers that have a rating on ABCL. Out of the 2 peers that are also analyzing ABCL, 0 agree with Scott's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Scott
- Robert Wasserman of "Benchmark" Upgraded from Hold to Strong Buy on, Thursday, February 22nd, 2024
- Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $17 on, Wednesday, February 21st, 2024
Contributing Sources